Telemedicine and Clinical Outcomes in Peritoneal Dialysis: A Propensity-Matched Study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Xiao, Ma Tiantian, Tian Xue, Li Shaomei, Pei Huaying, Zhao Jinghong, Zhang Ying, Xiong Zibo, Liao Yumei, Li Ying, Lin Qiongzhen, Hu Wenbo, Li Yulin, Zheng Zhaoxia, Duan Liping, Fu Gang, Guo Shanshan, Zhang Beiru, Yu Rui, Sun Fuyun, Ma Xiaoying, Hao Li, Liu Guiling, Zhao Zhanzheng, Xiao Jing, Shen Yulan, Zhang Yong, Du Xuanyi, Ji Tianrong, Wang Caili, Deng Lirong, Yue Yingli, Chen Shanshan, Ma Zhigang, Li Yingping, Zuo Li, Zhao Huiping, Zhang Xianchao, Wang Xuejian, Liu Yirong, Gao Xinying, Chen Xiaoli, Li Hongyi, Du Shutong, Zhao Cui, Xu Zhonggao, Zhang Li, Chen Hongyu, Li Li, Wang Lihua, Yan Yan, Ma Yingchun, Wei Yuanyuan, Zhou Jingwei, Li Yan, Zheng Yingdong, Wang Jinwei, Zhao Minghui, Dong Jie, PDTAP working group
Аннотация
METHODS: The Peritoneal Dialysis Telemedicine-assisted Platform Cohort Study (PDTAP Study) was conducted prospectively in 27 hospitals in China since 2016. Patient and practice data were collected through the doctor-end of the TM app (Manburs) for all participants. TM including self-monitoring records, on-line education materials, and real-time physician-patient contact was only performed for the patient-end users of the Manburs. The primary outcome was all-cause mortality. The secondary outcomes were cause-specific mortality and all-cause and cause-specific permanent transfer to hemodialysis.
RESULTS: A total of 7,539 PD patients were enrolled between June 2016 and April 2019, with follow-up till December 2020. Patients were divided into two cohorts: TM group (39.1%) and non-TM group (60.9%). A propensity score was used to create 2,160 matched pairs in which the baseline covariates were well-balanced. There were significantly lower risks of all-cause mortality (HR 0.59 [0.51, 0.67], p < 0.001), CVD mortality (HR 0.59 [0.49, 0.70], p < 0.001), all-cause transfer to hemodialysis (0.57 [0.48, 0.67], p < 0.001), transfer to hemodialysis from PD-related infection (0.67 [0.51, 0.88], p = 0.003), severe fluid overload (0.40 [0.30, 0.55], p < 0.001), inadequate solute clearance (0.49 [0.26, 0.92], p = 0.026), and catheter-related noninfectious complications (0.41 [0.17, 0.97], p = 0.041) in the TM group compared with the non-TM group.
CONCLUSION: This study indicated real-world associations between TM usage and reduction in patient survival and technique survival through a multicenter prospective cohort.